Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability

Digestive Diseases and Sciences
G R DaviesD S Rampton

Abstract

In previous open studies, misoprostol and metronidazole reduced nonsteroidal anti-inflammatory drug-induced intestinal permeability changes and inflammation respectively. We assessed the effects of indomethacin treatment (50 mg three times a day) for one week with either coadministered metronidazole (400 mg twice a day, group 1, N = 9) or misoprostol (200 micrograms four times a day, group 2, N = 7) on intestinal permeability to [51Cr]EDTA and mannitol in healthy volunteers, using double-blind, placebo-controlled, randomized techniques. Given alone, neither metronidazole nor misoprostol affected [51Cr]EDTA permeation, whereas indomethacin alone increased it from 1.20 (0.40) [mean percent urinary recovery (SD) groups 1 and 2] to 2.43 (0.72), P < 0.002. Coadministered metronidazole (group 1) prevented this increase [1.10 (0.39) before, 1.55 (0.54) after, P > 0.05], whereas misoprostol (group 2) did not [1.31 (0.51) before, 3.26 (1.10) after, P = 0.005]. No drug regimen altered mannitol permeation. Indomethacin and misoprostol did not affect urinary recovery of intravenously administered probes. The results with metronidazole, if related to its antibacterial effects, support evidence from animal models that bacteria contribute to ...Continue Reading

References

Jan 1, 1977·International Archives of Allergy and Applied Immunology·D I GroveK S Warren
Sep 3, 1979·Clinica Chimica Acta; International Journal of Clinical Chemistry·M F Laker, W G Gunn
Oct 1, 1975·Biochemical Pharmacology·D E DugganK C Kwan
Jul 1, 1991·Annals of Clinical Biochemistry·J BloodP G Hill
Mar 1, 1989·Digestive Diseases and Sciences·I BjarnasonA J Levi
Jan 1, 1989·Scandinavian Journal of Gastroenterology. Supplement·I BjarnasonT Peters
Dec 24, 1988·BMJ : British Medical Journal·I BjarnasonA J Levi
Mar 1, 1986·Agents and Actions·P Del SoldatoC Scarpignato
Jan 1, 1987·Scandinavian Journal of Gastroenterology·D S Rampton
May 1, 1986·British Journal of Rheumatology·G C Zaphiropoulos
Sep 1, 1985·Annals of the Rheumatic Diseases·J T BourneJ A Wojtulewski
Nov 1, 1985·Digestive Diseases and Sciences·G SchoenhardF E Kohn
Nov 1, 1985·Digestive Diseases and Sciences·J A Steiner
Jul 1, 1981·Clinical Pharmacokinetics·L Helleberg

❮ Previous
Next ❯

Citations

Aug 26, 1998·The American Journal of Medicine·B Cryer, M B Kimmey
May 24, 2003·Best Practice & Research. Clinical Gastroenterology·Reiner Wiest, Heiko C Rath
Aug 5, 1998·Alimentary Pharmacology & Therapeutics·N M Davies
Aug 6, 1999·Journal of Pediatric Gastroenterology and Nutrition·R E KimuraJ D Lloyd-Still
Apr 28, 2005·Chemotherapy·Carmelo Scarpignato, Iva Pelosini
Feb 25, 2006·Digestion·Angel Lanas, Carmelo Scarpignato
Oct 27, 2010·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Chaitanya AreEugene Greenberg
Feb 12, 2002·Pharmacotherapy·Imad F Btaiche, Nabil Khalidi
Dec 20, 2011·World Journal of Gastroenterology : WJG·Sung Chul ParkDonggeun Sul
Apr 10, 2013·World Journal of Gastroenterology : WJG·John L Wallace
Feb 20, 2009·Journal of Gastroenterology·Ingvar Bjarnason, Ken Takeuchi
Aug 10, 2012·Journal of Gastroenterology·Massimo MontaltoRaffaele Landolfi
Apr 4, 2013·BMC Research Notes·Won Seok ParkHo Sung Park
Dec 12, 2012·Journal of Digestive Diseases·Carla J Gargallo, Angel Lanas
Feb 1, 1996·Baillière's Clinical Rheumatology·I Bjarnason, T J Peters
Jul 16, 2014·BioMed Research International·Manjusha ChoudharySurender Singh
Jan 1, 1995·Arthritis and Rheumatism·D R LichtensteinM M Wolfe
Feb 14, 2018·Current Opinion in Gastroenterology·Foong Way David Tai, Mark E McAlindon
Oct 21, 2016·Clinical and Translational Gastroenterology·Julia KönigRobert-Jan Brummer
Apr 24, 2010·European Journal of Clinical Investigation·Shunji FujimoriChoitsu Sakamoto
Jul 1, 2020·Terapevticheskiĭ arkhiv·E N Kareva
Aug 28, 2020·Frontiers in Pharmacology·Damian Maseda, Emanuela Ricciotti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.